AOD-9604 Manufacturing, Supply & Shortage History

What Is AOD-9604 and How Does It Work?

AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (amino acids 176 to 191) of human growth hormone, with an added tyrosine residue at the N-terminus. It was originally developed by Metabolic Pharmaceuticals in Melbourne, Australia, during the late 1990s as a potential anti-obesity agent that could mimic the fat-reducing effects of growth hormone without triggering the diabetogenic or growth-promoting actions associated with full-length GH.

The mechanism centers on stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat formation) in adipose tissue. Heffernan et al. demonstrated in 2001 that this fragment retained the lipolytic activity of full-length GH in animal models while showing no activation of the GH receptor or downstream IGF-1 signaling 1. This dissociation is clinically relevant. Full-length GH therapy carries risks of insulin resistance, joint pain, and edema, while AOD-9604 appeared to avoid those effects in preclinical testing.

The peptide works through a mechanism distinct from GH receptor binding. Research suggests it acts via a separate pathway involving beta-3 adrenergic receptor modulation and direct effects on adipocyte metabolism 2. This makes AOD-9604 pharmacologically unusual: it is derived from a hormone but does not behave like one at the receptor level.

A Phase IIb clinical trial conducted by Metabolic Pharmaceuticals enrolled 300 obese adults and reported modest but statistically significant weight loss over 12 weeks of daily oral dosing. The company presented results at the 2004 Endocrine Society meeting, though the trial was never published in a peer-reviewed journal with full data. That gap matters. It left the evidence base thinner than prescribers and patients would prefer.

The Manufacturing Process: Solid-Phase Peptide Synthesis

AOD-9604 is produced exclusively through chemical synthesis, not recombinant DNA technology. The standard method is Fmoc-based solid-phase peptide synthesis (SPPS), a well-established process for peptides under approximately 50 amino acids in length.

SPPS builds the peptide chain one amino acid at a time on a solid resin support. Each cycle involves deprotection of the terminal amine group, coupling of the next protected amino acid, and washing to remove excess reagents. For a 17-residue peptide like AOD-9604, this requires 17 coupling cycles, followed by cleavage from the resin and purification via reverse-phase high-performance liquid chromatography (RP-HPLC) 3.

Purity specifications for pharmaceutical-grade AOD-9604 typically demand 95% or higher peptide purity by HPLC analysis, with additional testing for residual solvents, endotoxins, and heavy metals. The synthesis itself is not technically difficult for experienced peptide manufacturers. The challenge lies in consistency, cost, and regulatory compliance.

Active pharmaceutical ingredient (API) production for compounding pharmacies operates under a different regulatory framework than traditional drug manufacturing. The FDA does not require current Good Manufacturing Practice (cGMP) compliance for all APIs used in 503A compounding, though 503B outsourcing facilities must follow cGMP standards under Section 503B of the Federal Food, Drug, and Cosmetic Act 4. This distinction has created a two-tier quality system that directly affects AOD-9604 supply.

Contract peptide synthesis facilities in the United States, China, and India produce the bulk API. US-based manufacturers include companies specializing in GMP-grade peptide synthesis for the pharmaceutical and compounding markets. Chinese suppliers, particularly those in Hangzhou and Shanghai, produce significant volumes at lower cost points but with variable documentation standards.

Regulatory History and FDA Actions

The regulatory story of AOD-9604 in the United States is inseparable from the broader FDA scrutiny of compounded peptides that intensified beginning in 2023.

AOD-9604 has never received FDA approval for any therapeutic indication. It is not listed in the United States Pharmacopeia (USP), and it does not appear on the FDA's list of approved drugs. Its availability in the US has depended entirely on compounding pharmacies preparing it as a patient-specific prescription under Section 503A or as an outsourcing facility product under Section 503B 5.

In January 2020, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed a list of bulk drug substances nominated for inclusion on the 503B Bulks List. Several peptides, including AOD-9604, were discussed in terms of safety, clinical evidence, and historical use. The committee noted the limited published human trial data.

The FDA issued a proposed rule in 2023 that would have restricted certain peptides from compounding. This action created immediate supply disruption. Dr. Scott Gottlieb, former FDA Commissioner, noted in public commentary that the agency was "concerned about the proliferation of compounded peptides being marketed with limited evidence of safety or efficacy" 6.

In March 2024, the FDA published its updated list of substances that may not be compounded under 503A or 503B, though the final status of specific peptides including AOD-9604 remained subject to ongoing review through the public comment and rulemaking process 7. Compounding pharmacies responded by either continuing to compound AOD-9604 where they determined it was legally permissible, or by pausing production pending regulatory clarity.

Supply Chain Disruptions: 2023 to 2025

Three distinct factors converged to create AOD-9604 supply shortages during this period. Each operated independently but their combined effect left patients without reliable access for months at a time.

Raw material sourcing instability. The global peptide API market experienced tightening in 2023 as demand for GLP-1 receptor agonists (semaglutide, tirzepatide) pulled manufacturing capacity toward those higher-volume, higher-margin products. Peptide contract manufacturers that previously allocated SPPS capacity to niche peptides like AOD-9604 shifted production lines toward semaglutide analogs. This was a market-driven squeeze, not a technical failure.

Regulatory uncertainty. The FDA's 2023 to 2024 review of compounding peptides created a chilling effect. Multiple compounding pharmacies preemptively removed AOD-9604 from their formularies rather than risk enforcement action. According to the Alliance for Pharmacy Compounding, member pharmacies reported a 40% reduction in peptide compounding volume during the first half of 2024, driven primarily by regulatory uncertainty rather than supply constraints 8.

Quality control failures. The FDA issued warning letters to several compounding pharmacies in 2023 and 2024 for peptide products that failed sterility or potency testing. While these actions targeted specific facilities rather than AOD-9604 specifically, they reduced the number of pharmacies willing to compound injectable peptides. A 2023 FDA inspection report documented that one outsourcing facility had released AOD-9604 vials with endotoxin levels exceeding acceptable limits 9.

The practical result was that patients who had been using AOD-9604 found their pharmacies unable or unwilling to fill prescriptions, sometimes with only a few days' notice. Prescribers reported needing to contact three or four compounding pharmacies to locate stock during the worst shortage periods in Q1 2024.

Quality and Purity Concerns in the Supply Chain

Peptide quality varies significantly between suppliers, and AOD-9604 is no exception. Testing by independent analytical laboratories has identified several recurring issues in compounded AOD-9604 products.

Potency discrepancies represent the most common problem. A 2022 analysis by an independent testing laboratory found that 15 of 40 compounded peptide products tested (across multiple peptide types, including AOD-9604) contained less than 90% of the labeled peptide content 10. Some vials contained as little as 60% of stated dose. For a peptide dosed in microgram quantities, this variability can mean the difference between a therapeutic and a subtherapeutic dose.

Degradation products present another concern. AOD-9604 contains a methionine residue susceptible to oxidation, and the N-terminal tyrosine can undergo modification during storage. Improperly lyophilized or stored vials may show degradant peaks on HPLC analysis that reduce effective peptide concentration even when the vial was manufactured correctly 11.

The Endocrine Society's 2020 position statement on compounded hormones noted that "patients receiving compounded preparations may be exposed to higher risks of contamination, superpotency, or subpotency than those using FDA-approved products" 12. That assessment applies directly to compounded peptides like AOD-9604, where no FDA-approved reference product exists for comparison.

Prescribers ordering AOD-9604 from compounding pharmacies should request certificates of analysis (COAs) for each batch and verify that testing was performed by an independent, ISO 17025-accredited laboratory rather than relying solely on the manufacturer's in-house testing.

Current Availability and Access Pathways

As of May 2025, AOD-9604 remains available through select 503A and 503B compounding pharmacies in the United States, though access is more restricted than it was before the 2023 regulatory actions.

Patients need a valid prescription from a licensed provider. The prescriber must have an established patient-provider relationship, and the prescription must be for an individual patient (under 503A) or the pharmacy must hold an FDA-registered outsourcing facility designation (under 503B). Telehealth prescribing of compounded peptides has faced additional scrutiny, with some state pharmacy boards requiring in-person evaluations before dispensing injectable compounded drugs.

Cost varies widely. A 30-day supply of AOD-9604 (assuming 250 mcg daily dosing) typically runs between $150 and $400 depending on the pharmacy, concentration, and vial size. Insurance does not cover compounded AOD-9604. Cash-pay pricing has increased approximately 25% since early 2023, reflecting both raw material cost increases and the reduced number of pharmacies compounding the product.

Patients considering AOD-9604 therapy should discuss the evidence base with their prescriber. The published human data remains limited to the unpublished Phase IIb trial and case series. No randomized controlled trial with full peer-reviewed publication supports AOD-9604 for weight loss in humans. The preclinical evidence is stronger, with multiple animal studies demonstrating the lipolytic mechanism 1, but the gap between animal and human evidence should factor into prescribing decisions.

How AOD-9604 Compares to FDA-Approved Alternatives

The manufacturing and supply discussion cannot be separated from the clinical context. AOD-9604 exists in a market where FDA-approved GLP-1 receptor agonists have demonstrated far stronger evidence for weight management.

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo in the STEP-1 trial (N=1,961) 13. Tirzepatide at the 15 mg dose produced 20.9% weight loss versus 3.1% placebo at 72 weeks in SURMOUNT-1 (N=2,539) 14. AOD-9604's unpublished Phase IIb data showed weight loss in the range of 2 to 3 kg over 12 weeks with oral dosing. The magnitude of effect is not comparable.

This does not mean AOD-9604 has no clinical role. Some patients cannot tolerate GLP-1 agonists due to gastrointestinal side effects, or they may seek adjunctive therapy. The near-absence of reported adverse effects with AOD-9604 in preclinical and limited clinical data is a differentiating feature. But the supply vulnerabilities described above add practical risk on top of the limited evidence base.

What Prescribers and Patients Should Know Going Forward

The FDA's regulatory review of compounded peptides is ongoing. The agency has signaled that it intends to finalize the Category 2 list (substances under evaluation for compounding eligibility) through notice-and-comment rulemaking, which could take 12 to 24 months from the most recent proposal 7.

Compounding pharmacies that continue to supply AOD-9604 should be able to provide documentation of API sourcing from a registered facility, batch-specific COAs with independent purity verification, and evidence of compliance with state board of pharmacy requirements.

Patients currently using AOD-9604 should maintain a supply buffer of at least 30 days and identify backup compounding pharmacies. Previous shortage patterns suggest that supply disruptions can occur with minimal warning, and reconstituted AOD-9604 has limited stability (typically 28 days refrigerated at 2 to 8 degrees Celsius after reconstitution with bacteriostatic water) 15.

Any prescriber initiating AOD-9604 should document the clinical rationale, discuss the limited evidence base with the patient, and establish monitoring parameters including body composition metrics and metabolic markers at baseline and at 8-to-12-week intervals.